Alzheimer’s disease
-
PublishedJuly 12, 2023
Commentary: Alzheimer’s drug Leqembi gets full FDA nod, but hurdles remain
The rollout is likely to take longer than patients and their families would like.
-
PublishedJuly 6, 2023
FDA gives full approval for Alzheimer’s drug Leqembi, and Medicare will pay for it
The Food and Drug Administration endorsed the IV drug, Leqembi, for patients with mild dementia and other symptoms caused by early Alzheimer's disease.
-
PublishedFebruary 28, 2023
Games with grandfather inspire new chess club for those with memory loss
The idea for the club came from a Cape Elizabeth student who played the game with her grandfather, who had dementia but "always remembered how to play chess."
-
PublishedFebruary 1, 2023
Sen. Collins spearheads efforts to fund Alzheimer’s research
A bipartisan group of senators is proposing to boost funding for research and prevention through 2035.
-
PublishedJanuary 6, 2023
FDA approves Alzheimer’s drug that modestly slows disease
The drug, Leqembi, is the first that’s been convincingly shown to slow the decline in memory and thinking that defines Alzheimer’s by targeting the disease's underlying biology.
-
PublishedNovember 29, 2022
Drug slows Alzheimer’s but can it make a real difference?
New data shows an experimental Alzheimer's drug modestly slowed the brain disease's inevitable worsening.
-
PublishedOctober 12, 2022
Maine Voices: The long goodbye – my family, my father and Alzheimer’s
The disease’s progression tests our ties, but maybe a cure is in the pipeline so other families will not have to endure what we and many millions of others do each day.
-
PublishedOctober 10, 2022
Walk to End Alzheimer’s returns to downtown Brunswick Oct. 15
The annual Midcoast Area Walk to End Alzheimer’s starts with registration at 9 a.m. Saturday at the Maine Street mall and gazebo, with a welcome ceremony at 10 a.m. and walk start at 10:30 a.m.
-
PublishedSeptember 28, 2022
Gov. Mills launches program to give grants up to $2,000 to family caregivers
The $5.1 million program is for family caregivers of patients with disabilities, such as Alzheimer's and dementia, who are being cared for at home.
-
PublishedSeptember 27, 2022
Experimental Alzheimer’s drug slows cognitive decline in trial, firms say
Makers of the drug have already applied to the Food and Drug Administration for accelerated approval for lecanemab, based on earlier-stage data.
- 1
- 2
- 3
- 4
- Next Page →